Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00785291
What this trial is testing

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+6 more
National Cancer Institute (NCI) 799
Testing effectiveness (Phase 2)WithdrawnNCT01612910
What this trial is testing

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Who this might be right for
Breast Cancer Female
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT07616453
What this trial is testing

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Testing effectiveness (Phase 2)Ended earlyNCT02269670
What this trial is testing

Phase II Study of Everolimus Beyond Progression

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast Cancer+5 more
Emory University 3
Testing effectiveness (Phase 2)Study completedNCT02536742
What this trial is testing

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 124
Testing effectiveness (Phase 2)Temporarily pausedNCT04946864
What this trial is testing

Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Who this might be right for
Breast CancerSolid Tumor, Adult
Ascentage Pharma Group Inc. 65
Large-scale testing (Phase 3)Active Not RecruitingNCT05296798
What this trial is testing

Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 922
Testing effectiveness (Phase 2)Study completedNCT04436744
What this trial is testing

Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 221
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Large-scale testing (Phase 3)Study completedNCT02980965
What this trial is testing

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Who this might be right for
Breast Cancer Female
Fudan University 249
Large-scale testing (Phase 3)Ended earlyNCT04460807
What this trial is testing

Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Who this might be right for
Ovarian Cancer
Ente Ospedaliero Ospedali Galliera 23
Early research (Phase 1)Study completedNCT06547164
What this trial is testing

Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Who this might be right for
Healthy Participants
AstraZeneca 40
Testing effectiveness (Phase 2)Study completedNCT04588298
What this trial is testing

Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
AstraZeneca 135
Testing effectiveness (Phase 2)Looking for participantsNCT06110793
What this trial is testing

Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 56
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Early research (Phase 1)Study completedNCT01597388
What this trial is testing

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
AstraZeneca 99
Testing effectiveness (Phase 2)Study completedNCT00084396
What this trial is testing

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Who this might be right for
Breast Cancer
Washington University School of Medicine 115
Not applicableLooking for participantsNCT03723928
What this trial is testing

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+3 more
SWOG Cancer Research Network 739
Early research (Phase 1)Looking for participantsNCT04872166
What this trial is testing

BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Who this might be right for
Advanced Solid TumorMetastatic Breast Cancer
Edgewood Oncology Inc. 112
Next Page